Evidence map›Paper›PMID 41626435›Full record

ArticleACS omega2026

Respiratory Syncytial Virus F Protein Adjuvanted with a Carbomer-Based Adjuvant Induces Protective Humoral Response in Mice.

Shivam Singh, Balwant Singh, Bhisma Narayan Panda, Thomas Cleven, Marulasiddappa Suresh, Guruprasad R Medigeshi

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shivam SinghClinical and Cellular Virology Lab, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
Balwant SinghClinical and Cellular Virology Lab, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
Bhisma Narayan PandaExperimental Animal Facility, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
Thomas ClevenDepartment of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Marulasiddappa SureshDepartment of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Guruprasad R MedigeshiClinical and Cellular Virology Lab, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.ORCID https://orcid.org/0000-0001-5333-9743

Funding

Novel Combination Adjuvant for Eliciting Systemic and Mucosal CD8 T Cell MemoryU01AI124299 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KLEIN, BRUCE STEVEN, SURESH, MARULASIDDAPPA · 2016 to 2025
$6.2M
Vaccine-Induced Mucosal T-Cell Immunity to Respiratory Viruses in Dirty MiceR21AI173757 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI SURESH, MARULASIDDAPPA · 2023 to 2024
$428k
NIAID NIH HHS R21 AI173757NIAID NIH HHS U01 AI124299
6 · The paper itself

Abstract

Carbomer-lecithin-based adjuvant Adjuplex has been shown to induce a balanced T cell response and high antibody titers with some of the viral pathogens. Here, we compared the humoral immune response in mice immunized intranasally with respiratory syncytial virus fusion (RSV-F) or glycoprotein (RSV-G) or both using Adjuplex and/or a TLR9 agonist, CpG oligodeoxynucleotide (ODN). Both the adjuvants elicited robust antibody response in mice; however, Adjuplex generated higher levels of neutralizing antibodies as compared to CpG ODN when used with RSV-F protein. Neutralizing antibody titers were associated with reduced RSV load in the lungs of immunized BALB/c mice upon intranasal challenge with the RSV A2 strain. RSV-G alone was insufficient to elicit a strong antibody response with either of the adjuvants, and combining RSV-F and RSV-G did not show any synergistic response in terms of neutralizing antibody titers; however, this combination of antigens elicited a strong mucosal immune response as measured by IgA titers specific to RSV-F and RSV-G in lung tissues. These data suggest that carbomer-based adjuvants can induce a potent and protective humoral and mucosal response when used as an adjuvant for the RSV-F subunit vaccine, and the combination of RSV-F and RSV-G with Adjuplex may further be explored for enhancing the efficacy of RSV vaccines.

Identifiers

PMID41626435
PMCPMC12854629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.